PL3324932T3 - Kompozycje i sposoby dla liofiliozwanych postaci nanocząstek - Google Patents

Kompozycje i sposoby dla liofiliozwanych postaci nanocząstek

Info

Publication number
PL3324932T3
PL3324932T3 PL16828602T PL16828602T PL3324932T3 PL 3324932 T3 PL3324932 T3 PL 3324932T3 PL 16828602 T PL16828602 T PL 16828602T PL 16828602 T PL16828602 T PL 16828602T PL 3324932 T3 PL3324932 T3 PL 3324932T3
Authority
PL
Poland
Prior art keywords
nanoparticle
compositions
methods
lyophile forms
lyophile
Prior art date
Application number
PL16828602T
Other languages
English (en)
Inventor
Wenbin Ying
Roger Adami
Yuwei Wang
Haiqing Yin
Liping Wang
Dong Liu
Original Assignee
Nitto Denko Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corporation filed Critical Nitto Denko Corporation
Publication of PL3324932T3 publication Critical patent/PL3324932T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16828602T 2015-07-22 2016-07-22 Kompozycje i sposoby dla liofiliozwanych postaci nanocząstek PL3324932T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562195356P 2015-07-22 2015-07-22
EP16828602.9A EP3324932B1 (en) 2015-07-22 2016-07-22 Compositions and methods for nanoparticle lyophile forms
PCT/US2016/043537 WO2017015552A1 (en) 2015-07-22 2016-07-22 Compositions and methods for nanoparticle lyophile forms

Publications (1)

Publication Number Publication Date
PL3324932T3 true PL3324932T3 (pl) 2021-07-05

Family

ID=57834582

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16828602T PL3324932T3 (pl) 2015-07-22 2016-07-22 Kompozycje i sposoby dla liofiliozwanych postaci nanocząstek

Country Status (23)

Country Link
US (3) US10300018B2 (pl)
EP (1) EP3324932B1 (pl)
JP (2) JP6875373B2 (pl)
KR (1) KR102716928B1 (pl)
CN (2) CN113679689B (pl)
AU (1) AU2016297153B2 (pl)
CA (1) CA2992849C (pl)
CY (1) CY1123984T1 (pl)
DK (1) DK3324932T3 (pl)
EA (1) EA035761B1 (pl)
ES (1) ES2862191T3 (pl)
HR (1) HRP20210523T1 (pl)
HU (1) HUE053990T2 (pl)
IL (2) IL288342B2 (pl)
LT (1) LT3324932T (pl)
MX (1) MX373982B (pl)
PL (1) PL3324932T3 (pl)
PT (1) PT3324932T (pl)
RS (1) RS61607B1 (pl)
SI (1) SI3324932T1 (pl)
SM (1) SMT202100196T1 (pl)
TW (1) TWI732773B (pl)
WO (1) WO2017015552A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017015552A1 (en) * 2015-07-22 2017-01-26 Nitto Denko Corporation Compositions and methods for nanoparticle lyophile forms
US20210069121A1 (en) 2017-12-12 2021-03-11 Lead Biotherapeutics Ltd Solid lipid nanoparticle for intracellular release of active substances and method for production the same
CN108813619A (zh) * 2018-07-19 2018-11-16 广州市汉廷食品有限公司 一种无公害食品添加剂及其制备工艺
CA3111476A1 (en) 2018-09-28 2020-04-02 Nutcracker Therapeutics, Inc. Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
PT3880212T (pt) * 2018-11-16 2024-02-08 Nitto Denko Corp Formulação e métodos de administração de rna de interferência para tumores malignos
WO2021060440A1 (ja) * 2019-09-26 2021-04-01 日油株式会社 脂質ナノ粒子の凍結乾燥組成物
WO2021174149A2 (en) * 2020-02-28 2021-09-02 Microcures, Inc. Fidgetin-like 2 as a target to enhance wound healing
IL297450A (en) * 2020-04-20 2022-12-01 Univ Texas Compositions of biologically active dry powder, methods for production and use
CA3191874A1 (en) 2020-08-14 2022-02-17 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
CN116367718A (zh) 2020-10-02 2023-06-30 国立大学法人北海道大学 脂质纳米粒子
TW202334415A (zh) 2021-10-14 2023-09-01 美商止血治療股份有限公司 治療與膽汁酸轉運體相關之疾病的組合物及方法
KR102712873B1 (ko) * 2021-12-20 2024-10-04 고려자연식품(주) 과일향기 포집을 위한 나노 지질 전달체 제조와 분말화 방법
CN116643056B (zh) * 2022-02-15 2025-02-18 厦门万泰凯瑞生物技术有限公司 促甲状腺激素受体复合物、试剂盒、制备方法和用途
WO2024151942A2 (en) 2023-01-13 2024-07-18 Hemoshear Therapeutics, Inc. Sirnas targeting slc10a1 transcripts, compositions and uses thereof
WO2025015189A1 (en) * 2023-07-13 2025-01-16 Comanche Biopharma Corp. Formulations of nucleic acid compounds and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537683A (en) 1982-02-01 1985-08-27 Rohm And Haas Company Trihalomethane precursor removal using ion exchange emulsions
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
KR101268258B1 (ko) * 2002-09-06 2013-05-31 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
AU2004251680B2 (en) 2003-06-04 2010-02-18 Georgetown University Method for improving stability and shelf-life of liposome complexes
AU2005302255A1 (en) 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
CA2587337A1 (en) * 2004-11-19 2006-05-26 Novosom Ag Improvements in or relating to pharmaceutical compositions for local administration
JP5334170B2 (ja) * 2007-02-09 2013-11-06 国立大学法人 奈良先端科学技術大学院大学 Ｃ７０含有リポソームおよびその製造方法、並びにその利用
CN102811743B (zh) * 2009-12-11 2015-11-25 佰恩德治疗股份有限公司 冻干治疗颗粒的稳定制剂
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
WO2011119995A2 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
CN102018672B (zh) * 2010-11-29 2013-09-18 广州朗圣药业有限公司 一种水溶性药物的脂质体冻干组合物及其制备方法
DK3336082T3 (da) 2011-06-08 2020-04-27 Translate Bio Inc Spaltelige lipider
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
KR102284689B1 (ko) 2011-10-21 2021-08-02 셀라토 파마슈티칼즈, 인코포레이티드 동결건조된 리포좀
CA2853689C (en) * 2011-11-04 2020-06-30 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
US9579338B2 (en) 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
WO2013149013A1 (en) 2012-03-28 2013-10-03 Discovery Laboratories, Inc. Lyophilization of synthetic liposomal pulmonary surfactant
JP6211054B2 (ja) * 2012-03-29 2017-10-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 脂質誘導される中性ナノ粒子
AU2013270685B2 (en) 2012-06-08 2017-11-30 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations
US20140271815A1 (en) 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
WO2017015552A1 (en) * 2015-07-22 2017-01-26 Nitto Denko Corporation Compositions and methods for nanoparticle lyophile forms

Also Published As

Publication number Publication date
US20170020819A1 (en) 2017-01-26
IL288342B2 (en) 2024-02-01
MX373982B (es) 2020-07-15
US12311055B2 (en) 2025-05-27
EP3324932A1 (en) 2018-05-30
SI3324932T1 (sl) 2021-07-30
DK3324932T3 (da) 2021-04-06
IL288342B1 (en) 2023-10-01
ES2862191T3 (es) 2021-10-07
RS61607B1 (sr) 2021-04-29
IL257029A (en) 2018-03-29
US20190231695A1 (en) 2019-08-01
IL257029B (en) 2021-12-01
CY1123984T1 (el) 2022-05-27
MX2018000891A (es) 2018-06-11
JP2018521083A (ja) 2018-08-02
JP6875373B2 (ja) 2021-05-26
US10300018B2 (en) 2019-05-28
TW201717914A (zh) 2017-06-01
EA035761B1 (ru) 2020-08-06
CN113679689A (zh) 2021-11-23
JP2021119161A (ja) 2021-08-12
EP3324932A4 (en) 2019-03-06
CN113679689B (zh) 2023-09-01
JP7268079B2 (ja) 2023-05-02
BR112018001178A2 (pt) 2018-09-11
TWI732773B (zh) 2021-07-11
KR102716928B1 (ko) 2024-10-11
LT3324932T (lt) 2021-04-26
AU2016297153A1 (en) 2018-03-01
PT3324932T (pt) 2021-04-06
SMT202100196T1 (it) 2021-05-07
KR20180030698A (ko) 2018-03-23
HUE053990T2 (hu) 2021-08-30
IL288342A (en) 2022-01-01
CA2992849C (en) 2023-06-13
US11737982B2 (en) 2023-08-29
US20240000710A1 (en) 2024-01-04
AU2016297153B2 (en) 2021-02-25
CN108024957A (zh) 2018-05-11
EP3324932B1 (en) 2021-03-10
CA2992849A1 (en) 2017-01-26
WO2017015552A1 (en) 2017-01-26
CN108024957B (zh) 2021-08-24
EA201890367A1 (ru) 2018-06-29
HRP20210523T1 (hr) 2021-05-14

Similar Documents

Publication Publication Date Title
IL288342A (en) Formulations and methods for lyophilic nanoparticulate forms
IL286025A (en) Nanoparticle preparations and immunotherapy methods
IL259576A (en) Preparations and methods for immuno-oncology
GB2546350B (en) Compositions and methods
GB2535253B (en) Compositions and methods
GB201718801D0 (en) Compositions and methods for inhibiting factor D
GB201718876D0 (en) Antithrombin-heparin compositions and methods
IL258292A (en) Methods and compositions for reducing metastases
PT3200815T (pt) Métodos e composições para o tratamento de cancro
IL246879B (en) Preparations of Epilimod and methods of using them
ZA201605109B (en) Compositions and methods for treating neutropenia
IL258222A (en) Compositions and methods for inhibiting beta-lactamase
GB201715820D0 (en) Compositions and methods
IL253174A0 (en) Nanoparticles and methods for their preparation
GB201705626D0 (en) Compositions and methods
ZA201807665B (en) Methods and compositions
GB201512996D0 (en) Compositions and methods
PT3160263T (pt) Composições para prevenção de infeções
GB201514413D0 (en) Compositions and methods
PL2990058T3 (pl) Ulepszone kompozycje i sposoby dla kompleksów fruktoboranowych
PT3210628T (pt) Métodos para complexos de frutoborato
GB201520755D0 (en) Nanoparticle formulations and their uses
GB201402915D0 (en) Compositions and methods
ZA201807782B (en) Methods and compositions
IL256261B (en) Hide1 compositions and methods